Patents by Inventor Srividya Swaminathan

Srividya Swaminathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED NK CELLS
    Publication number: 20240016838
    Abstract: Provided herein, inter alia, are compositions including engineered NK cells and methods for preparing the same. The engineered NK cells provided herein include integrated nucleic acid sequences encoding Cas9 proteins (e.g. dCas9). The engineered NK cells are contemplated to be effective for treating and/or preventing cancer, particularly leukemia.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 18, 2024
    Inventors: Srividya Swaminathan, Anil Kumar, Sung June Lee, Adeleh Taghi Khani, Chun-Wei Chen
  • Profiling and treatment of MYC-associated cancers with NK cells and type 1 interferon
    Patent number: 11648275
    Abstract: Compositions and methods are provided for classification and treatment of MYC-driven cancers, i.e. causally dependent on MYC as a result of, over-expression of MYC, constitutive expression of MYC, chromosomal translocation resulting in overactive MYC, and the like. Specifically, the methods comprising determining the MYC status of the cancer, and in a cancer that is determined to be driven by MYC activation, administering a composition of an effective dose of one or both of activated natural killer (NK) cells and a type 1 interferon.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: May 16, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Srividya Swaminathan, Dean W. Felsher, Holden Terry Maecker
  • PROFILING AND TREATMENT OF MYC-ASSOCIATED CANCERS
    Publication number: 20200353000
    Abstract: Compositions and methods are provided for classification and treatment of MYC-driven cancers, i.e. causally dependent on MYC as a result of, over-expression of MYC, constitutive expression of MYC, chromosomal translocation resulting in overactive MYC, and the like. Specifically, the methods comprising determining the MYC status of the cancer, and in a cancer that is determined to be driven by MYC activation, administering a composition of an effective dose of one or both of activated natural killer (NK) cells and a type 1 interferon.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 12, 2020
    Inventors: Srividya Swaminathan, Dean W. Felsher, Holden Terry Maecker